Modra

A novel oral formulation technology in oncology to improve delivery and bioavailability of chemotherapy

Switching from intravenous (IV)-to-oral treatment reduces side effects, improves patient convenience and allows options for modern combinatorial cancer treatment regimens

Learn more

News

Modra Pharmaceuticals Announces Start of Phase II Study for its Lead Oral Chemotherapy in Patients with Metastatic Prostate Cancer
Read more

the IV to Oral switch

improving patient lives
Learn more

Events

No current events
Read more